Categories: News

Nova Leap Health Corp. to Force Conversion of 8% Convertible Debentures due December 30, 2024

FacebookFacebookTwitterTwitterEmailEmailLinkedInLinkedInWhatsAppWhatsAppMessengerMessengerFlipboardFlipboardGmailGmailTelegramTelegramShareShare

NOT FOR DISSEMINATION IN THE UNITED STATES OR FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES

HALIFAX, Nova Scotia, Feb. 01, 2021 (GLOBE NEWSWIRE) — NOVA LEAP HEALTH CORP. (TSXV: NLH) (“Nova Leap” or “the Company”), a 2019 TSX Venture 50™ ranked company focused on the home health care industry, is pleased to announce that it has provided notice to holders of the Company’s 8.0% unsecured subordinated convertible debentures due December 30, 2024 with a principal amount of CAD$2,151,000 (the “Debentures”) that Nova Leap will be exercising its option to convert the entire principal amount of Debentures outstanding into common shares of the Company (“Common Shares”) at a conversion price of CAD$0.52 (the “Forced Conversion”). Prior to this, CAD$187,000 of the debentures due December 30, 2024 were voluntarily converted at a conversion price of CAD$0.52.

Pursuant to the terms of the Debentures, if, at any time after the first anniversary of the issue date of the Debentures, the daily volume weighted average price of the Common Shares on the TSX Venture Exchange exceeds CAD$0.78 for 20 consecutive trading days, the Company may elect to exercise its right of Forced Conversion. The Forced Conversion is expected to be completed on or about March 3, 2021. Accrued and unpaid interest under the Debentures to the conversion date will be paid to the holders in accordance with the Debentures.

About Nova Leap

Nova Leap is an acquisitive home health care services company operating in one of the fastest-growing industries in the U.S. & Canada. The Company performs a vital role within the continuum of care with an individual and family centered focus, particularly those requiring dementia care. Nova Leap achieved the #10 Ranking in the 2019 TSX Venture 50™ in the Clean Technology & Life Sciences sector. The Company is geographically diversified with operations in 7 different U.S. states within the New England and South-Central regions as well as Nova Scotia, Canada.

FORWARD LOOKING INFORMATION:

Certain information in this press release may contain forward-looking statements, such as statements regarding the completion of the Forced Conversion, future expansions and cost savings, the Company’s expected annualized recurring revenue run rate and plans regarding future acquisitions and financings. This information is based on current expectations and assumptions, including assumptions concerning general economic and market conditions, availability of working capital necessary for conducting Nova Leap’s operations, and Nova Leap’s ability to integrate its acquired businesses and maintain previously achieved service hour and revenue levels, that are subject to significant risks and uncertainties that are difficult to predict. Actual results might differ materially from results suggested in any forward-looking statements. Risks that could cause results to differ from those stated in the forward-looking statements in this release include the impact of the COVID-19 pandemic or any recurrence, including government regulations or voluntary measures limiting the Company’s ability to provide care to clients (such as shelter-in-place orders, isolation or quarantine orders, distancing requirements, or closures or restricted access procedures at facilities where clients reside), increased costs associated with personal protective equipment and sanitization supplies, staff and supply shortages; regulatory changes affecting the home care industry, other unexpected increases in operating costs and competition from other service providers. All forward-looking statements, including any financial outlook or future-oriented financial information, contained in this press release are made as of the date of this release and included for the purpose of providing information about management’s current expectations and plans relating to the future. The Company assumes no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those reflected in the forward-looking statements unless and until required by securities laws applicable to the Company. Additional information identifying risks and uncertainties is contained in the Company’s filings with the Canadian securities regulators, which filings are available at www.sedar.com.

CAUTIONARY STATEMENT:

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

CONTACT: For further information:

Chris Dobbin, CPA, CA
Director, President and CEO Nova Leap Health Corp.
T: 902 401 9480 F: 902 482 5177
E:cdobbin@novaleaphealth.com

Staff

Recent Posts

BioSig Technologies Confirms Full Compliance with Nasdaq Requirements for Continued Listing on The Nasdaq Capital Market

Los Angeles, CA, March 26, 2025 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (BSGM) (“BioSig” or…

1 hour ago

Dr. Lyudmila Sarder Receives Prestigious U.S. Congressional Award for Women’s History Month

"Trailblazing Physician and Advocate Receives U.S. Congressional Award for Advancing Healthcare Access and Community Service…

1 hour ago

InspireMD to Present at Upcoming 24th Annual Needham Virtual Healthcare Conference

MIAMI, March 26, 2025 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™…

1 hour ago

Relmada Therapeutics to Report Fourth Quarter 2024 Financial Results on Thursday, March 27, 2025

CORAL GABLES, Fla., March 26, 2025 (GLOBE NEWSWIRE) -- Relmada Therapeutics, Inc. (Nasdaq: RLMD, “Relmada”,…

1 hour ago

Zelluna ASA [ZLNA]: Notification of transaction by close associate of primary insider

Oslo, Norway, 26 March, 2025 Reference is made to the stock exchange notice published by…

1 hour ago

Silo Pharma Achieves Key Milestone with First Dosing in IND-Enabling GLP Study for SPC-15 as a Groundbreaking PTSD Treatment

Preclinical Data to Support Advancement Toward First-in-Human Clinical Trials SARASOTA, FL, March 26, 2025 (GLOBE…

1 hour ago